3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
7
Breast
5
Gynecologic
4
Gastrointestinal
4
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Classical hematology
1
Conditions
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
157
Nivolumab
132
Ipilimumab
77
Cyclophosphamide
46
Specimen Handling
44
Magnetic Resonance Spectroscopy
39
cemiplimab
35
Biopsy
31
fludarabine
28
trametinib
24
relatlimab
24
binimetinib
23
Interleukin-2
21
fludarabine phosphate
20
dabrafenib
20
atezolizumab
20
Radiotherapy
20
Opdualag
19
Radiosurgery
18
CTLA-4 Antigen
18
encorafenib
17
aldesleukin
17
Blood Specimen Collection
17
avelumab
14
Immunoglobulin G
14
Disulfides
13
lenvatinib
11
Bevacizumab
11
lifileucel
10
Paclitaxel
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Genetic Counseling
×
Dermatologic
×
1 year
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled